2022
Is CABG Indicated in Patients With Ischemic Cardiomyopathy?—Reply
Ahmad Y, Lansky AJ, Velazquez EJ. Is CABG Indicated in Patients With Ischemic Cardiomyopathy?—Reply. JAMA Cardiology 2022, 7: 1177-1177. PMID: 36223088, DOI: 10.1001/jamacardio.2022.3312.Peer-Reviewed Original Research
2018
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial
Lansky A, Wijns W, Xu B, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Baumbach A, Investigators T. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. The Lancet 2018, 392: 1117-1126. PMID: 30190206, DOI: 10.1016/s0140-6736(18)31649-0.Peer-Reviewed Original ResearchConceptsLate lumen lossStent late lumen lossTarget lesion failureCoronary artery diseaseNon-inferiority trialXience groupPrimary endpointLesion failureLumen lossAbluminal grooveAngiographic substudyComers populationArtery diseaseMyocardial ischaemiaMyocardial infarctionIschaemia-driven target lesion revascularisationAsymptomatic coronary artery diseaseTarget vessel myocardial infarctionIschemic coronary artery diseaseST-elevation myocardial infarctionRandom block allocationTarget lesion revascularisationStent thrombosis ratesVessel myocardial infarctionElevation myocardial infarction
2014
Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trials
Généreux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, LaSalle L, Xu K, McAndrew T, Kirtane A, Lansky AJ, Brener SJ, Mehran R, Stone GW. Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trials. Journal Of The American College Of Cardiology 2014, 63: 1845-1854. PMID: 24561145, DOI: 10.1016/j.jacc.2014.01.034.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSevere target lesion calcificationAcute coronary syndromePercutaneous coronary interventionTarget lesion calcificationTarget lesion revascularizationElevation acute coronary syndromeDefinite stent thrombosisLesion calcificationStent thrombosisHORIZONS-AMICoronary syndromeCoronary interventionCoronary calcificationST-segment elevation acute coronary syndromeSegment elevation acute coronary syndromesIndependent angiographic core laboratoryStable coronary artery diseaseSevere lesion calcificationOne-year outcomesElevation myocardial infarctionCoronary artery diseaseAngiographic core laboratoryACUITY trialIschemic outcomes
2012
Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial
Banai S, Finkelstein A, Almagor Y, Assali A, Hasin Y, Rosenschein U, Apruzzese P, Lansky AJ, Kume T, Edelman ER. Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial. American Heart Journal 2012, 165: 234-240.e1. PMID: 23351827, PMCID: PMC4637940, DOI: 10.1016/j.ahj.2012.10.023.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLate lossCoronary interventionDiabetes mellitusPrimary efficacy end pointBare metal stent implantationEnd pointSystemic innate immunityEfficacy end pointPlacebo-controlled trialPrimary end pointAcute coronary syndromeStent late lossMetal stent implantationSingle intravenous bolusVascular injury sitesAverage late lossBaseline monocyteLiposomal alendronateCoronary syndromePlacebo groupStudy drugCoronary narrowingOverall cohortPrespecified subgroups
2011
Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms Results From the Prospective Multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) Study
Koo BK, Erglis A, Doh JH, Daniels DV, Jegere S, Kim HS, Dunning A, DeFrance T, Lansky A, Leipsic J, Min JK. Diagnosis of Ischemia-Causing Coronary Stenoses by Noninvasive Fractional Flow Reserve Computed From Coronary Computed Tomographic Angiograms Results From the Prospective Multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) Study. Journal Of The American College Of Cardiology 2011, 58: 1989-1997. PMID: 22032711, DOI: 10.1016/j.jacc.2011.06.066.Peer-Reviewed Original ResearchConceptsFractional flow reserveCoronary artery diseaseComputation of FFRInvasive coronary angiographyNoninvasive fractional flow reserveCCTA stenosisCoronary angiographyDiagnostic performanceFlow reserveCCTA dataPredictive valueObstructive coronary artery diseaseMeasurement of FFRComputed Tomographic AngiogramsIschemia-causing stenosisPercent of patientsCoronary artery lesionsIndependent core laboratoryInvasive fractional flow reserveClinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial.
Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention 2011, 7: 307-13. PMID: 21729832, DOI: 10.4244/eijv7i3a54.Peer-Reviewed Original ResearchConceptsPaclitaxel-eluting stentsPercutaneous coronary interventionSegment restenosisYounger patientsElderly patientsLower incidenceSegment late lumen lossSegment late lossSPIRIT III trialTarget vessel failureLate lumen lossDrug-eluting stentsYears of ageThree-year resultsLower ratesAge-specific mechanismsStent assignmentAngiographic outcomesCoronary interventionIII trialsInducible ischaemiaEE patientsPE patientsLumen lossNeointimal response
2009
Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications
Pocock SJ, Mehran R, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Circulation 2009, 121: 43-51. PMID: 20026777, DOI: 10.1161/circulationaha.109.878017.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAged, 80 and overFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial IschemiaPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicRecombinant ProteinsRetrospective StudiesRisk FactorsConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsIndividual patient risk profileAcute coronary syndromePatient risk profileMajor bleedingMyocardial infarctionCoronary syndromeRisk profileHemorrhagic complicationsIndependent predictorsMortality rateUrgent Intervention Triage Strategy (ACUITY) trialAlternative antithrombotic regimensIndividual patient's riskRisk of deathCox regression modelTherapy of patientsSubsequent mortality ratesRelative treatment effectsAcute CatheterizationAntithrombotic regimensMajor bleedsAlternative pharmacotherapyStrategy trialImpact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy
Mehran R, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of Chronic Kidney Disease on Early (30-Day) and Late (1-Year) Outcomes of Patients With Acute Coronary Syndromes Treated With Alternative Antithrombotic Treatment Strategies An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovascular Interventions 2009, 2: 748-757. PMID: 19695543, DOI: 10.1016/j.jcin.2009.05.018.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryBiomarkersChronic DiseaseCoronary Artery BypassCreatinineDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHeparinHirudinsHumansKidney DiseasesLogistic ModelsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaOdds RatioPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsRisk AssessmentTime FactorsTreatment OutcomeTriageConceptsGlycoprotein IIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeBivalirudin monotherapyComposite ischemiaMajor bleedingCoronary syndromeClinical outcomesKidney diseaseHigh-risk acute coronary syndromesIIb/IIIa inhibitorsClinical adverse outcomesCreatinine clearance dataOutcomes of patientsNormal renal functionAdverse event ratesAntithrombotic treatment strategiesSignificant differencesACUITY trialIschemic outcomesRenal functionAdverse outcomesInvasive strategyLate outcomesTreatment strategies
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safety
2007
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, investigators F. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. The Lancet 2007, 369: 907-919. PMID: 17368152, DOI: 10.1016/s0140-6736(07)60450-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsCombined Modality TherapyDrug Therapy, CombinationEnoxaparinFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial IschemiaPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsPercutaneous coronary interventionAcute coronary syndromeNet clinical outcomeHigh-risk acute coronary syndromesUrgent Intervention Triage Strategy (ACUITY) trialCoronary interventionClinical outcomesMajor bleedingCoronary syndromeAcute CatheterizationStrategy trialDirect thrombin inhibitor bivalirudinAdverse ischemic eventsMajor haemorrhagic complicationsComparable clinical outcomesThrombin inhibitor bivalirudinHaemorrhagic complicationsIschemic eventsUnfractionated heparinSubgroup analysisProportion of individualsBivalirudinBleeding
2003
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation
Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, Lansky AJ, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. The American Journal Of Cardiology 2003, 92: 319-322. PMID: 12888144, DOI: 10.1016/s0002-9149(03)00637-4.Peer-Reviewed Original Research